“Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, shows promise as a therapeutic agent for conditions associated with inflammation and oxidative stress, often involving nitric oxide (NO) signaling dysregulation.

This review summarizes preclinical and clinical data on CBD’s impact on nitric oxide synthase (NOS) isoforms and NO levels in cardiovascular, neurological, metabolic, and immune systems.

Studies suggest that CBD can reduce inflammation-induced inducible NOS (iNOS) expression while maintaining or enhancing endothelial NOS (eNOS)-mediated NO production, leading to decreased oxidative stress, improved endothelial function, and reduced neuroinflammation.

The effects of CBD vary based on dose, formulation, timing, and disease state, with potential interactions with metabolites and other drugs affecting safety. Further research is needed to determine optimal dosing, formulation, pharmacokinetics, metabolite profiles, and long-term safety for specific conditions.”

https://pubmed.ncbi.nlm.nih.gov/41024292/

“In summary, the ongoing exploration of CBD’s interaction with NOS and its broader implications for human health underscores the need for rigorous scientific inquiry. As we continue to unravel its potential, the integration of cannabinoid-based therapies into mainstream medical practice could revolutionize approaches to treating chronic diseases characterized by inflammation and oxidative stress.”

“These findings suggest that CBD may serve as a promising cannabinoid-based therapeutic agent in treating chronic diseases associated with inflammation and oxidative stress. Overall, the review underscores the need for further research to explore the clinical applications of CBD and its mechanisms in various health scenarios, paving the way for evidence-based treatments that harness the therapeutic potential of cannabinoids.”

https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-025-00332-5